An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 28, 2010
Last updated: April 2, 2016
Last verified: April 2016
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.

Gastric Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Documentation of the testing process for HER2-positive tumors [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Assessment of implementation of guidelines and recommendations of Herceptin administration in routine clinical practice [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Documentation of backbone chemotherapy treatment and concomitant medication [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Quality of Life questionnaire [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Surveillance of pain intensity and analgesic consumption [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Surveillance of weight change [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Safety (incidence of adverse events) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 443
Study Start Date: April 2010
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Gastric cancer patients receiving Herceptin in routine clinical practice

Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease
  • HER2-positive tumor
  • Patients who are eligible for treatment with Herceptin according to the judgment of the physician

Exclusion Criteria:

  • Unwilling or unable to sign informed consent form
  • Any contraindications, interactions and incompatibilities to Herceptin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01220934

Frankfurt, Germany, 60488
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01220934     History of Changes
Other Study ID Numbers: ML22834 
Study First Received: September 28, 2010
Last Updated: April 2, 2016
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Site
Stomach Diseases processed this record on May 03, 2016